Skip to main content
. 2019 Jan 15;9(2):4. doi: 10.1038/s41408-018-0165-5

Fig. 2. Treatment with the BET inhibitor ABBV-075 depletes expression of super-enhancer regulated genes in AML cells.

Fig. 2

a–d MV4-11, OCI-AML5, MOLM13, and primary CD34+ AML cells were treated with the indicated concentrations of ABBV-075 for 4 h. Total RNA was isolated and reverse transcribed. The resulting cDNA was utilized for qPCR. The relative expression of each mRNA was normalized to GAPDH and compared to untreated cells (set at 1.0). e, f MV4-11 and OCI-AML5 cells were treated with the indicated concentrations of ABBV-075 for 24 h. Immunoblot analyses were conducted. The expression levels of β-Actin in the cell lysates served as the loading control. The numbers beneath the bands represent densitometry analysis